Options for sequential therapy in proliferative lupus nephritis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1428, 2004-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment Options for Proliferative Lupus Nephritis: An Update of Clinical Trial Evidence

By Navaneethan Sankar D.

Drugs, Vol. 68, Iss. 15, 2008-01 ,pp. : 2095-2104

Adis International

Access to resources Recommend Favorite

Defining the Role of Mycophenolate Mofetil in the Treatment of Proliferative Lupus Nephritis

By Lenz Oliver Fornoni Alessia Contreras Gabriel

Drugs, Vol. 65, Iss. 17, 2005-01 ,pp. : 2429-2436

Adis International

Access to resources Recommend Favorite

Low-dose fludarabine plus cyclophosphamide is effective in patients with proliferative lupus nephritis, but is associated with considerable adverse outcomes

Inpharma, Vol. 1, Iss. 1600, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Clinical Pathway for Monthly Pulse Intravenous Cyclophosphamide Therapy for Lupus Nephritis

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 42, Iss. 4, 2012-12 ,pp. : 278-282

John Wiley & Sons Inc

Access to resources Recommend Favorite

Animal Models of Lupus and Lupus Nephritis

Current Pharmaceutical Design, Vol. 21, Iss. 18, 2015-06 ,pp. : 2320-2349

Bentham Science Publishers

Access to resources Recommend Favorite